Immune-Onc Therapeutics, Inc. news
- IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors
- Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the dosing of the f
- Company announces completion of Phase 1 dose escalation ahead of schedule for IO-108, a first-in-class antibody targeting LILRB2 (ILT4)
- Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, as part of its clinical development programs in China.<
- IO-108 is the first LILRB2-targeting antibody administered to Chinese patients
- Implementation of IO-108 program in China initiates Immune-Onc’s global clinical development plan; Phase 1 trial has completed dose escalation in the U.S. in solid tumor patients
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the fir
- Multicenter Phase 1 study to evaluate IO-108 as both monotherapy and in combination with pembrolizumab in China
- Represents the first LILRB2-targeting antibody with IND clearance in China and the company’s fourth IND globally
- A Phase 1 trial evaluating IO-108 in patients with advanced solid tumors is currently enrolling in the U.S.
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage canc